AbbVie (ABBV) Cash & Equivalents (2012 - 2026)

AbbVie (ABBV) has reported Cash & Equivalents for 15 consecutive years, with $6.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 1.58% year-over-year to $6.6 billion in Q2 2026; TTM through Jun 2026 was $6.6 billion, a 1.58% increase from a year earlier, with the FY2025 full-year figure at $5.2 billion, down 5.34% from the prior year.
• Cash & Equivalents was $6.6 billion for Q2 2026 at AbbVie, down from $9.4 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $18.1 billion in Q1 2024 and troughed at $5.2 billion in Q1 2025.
• A 5-year average of $8.9 billion and a median of $7.9 billion in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 169.21% in 2024 and slumped 71.36% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $9.2 billion in 2022, then jumped by 39.27% to $12.8 billion in 2023, then slumped by 56.89% to $5.5 billion in 2024, then retreated by 5.34% to $5.2 billion in 2025, then advanced by 25.63% to $6.6 billion in 2026.
• The last three Cash & Equivalents figures came in at $6.6 billion (Q2 2026), $9.4 billion (Q1 2026), and $5.2 billion (Q4 2025), per Business Quant data.